Conformis, Inc. (CFMS) Research

Conformis, Inc., established in Billerica, Massachusetts in 2004, functions as a medical technology enterprise that designs, produces, and commercializes custom-fit medical devices and surgical instruments. Their product portfolio encompasses a variety of personalized knee replacement systems, including iUni and iDuo for addressing unicompartmental or bicompartmental knee osteoarthritis, the iTotal CR for cruciate-retaining total knee procedures, the iTotal PS for posterior-stabilized total knee replacements, as well as the iTotal Identity and Identity Imprint lines. Additionally, the company offers hip replacement options like the Conformis Hip System and Cordera products, and provides iJigs, which are personalized, single-use surgical guides. Conformis distributes these specialized solutions to orthopedic surgeons, hospitals, and other medical facilities through its dedicated sales force, independent representatives, and distributors, serving markets across the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, Oman, Italy, Poland, and other global regions.

Market snapshot

Symbol
CFMS
Price
$2.27
Day change
+0.44%
Market cap
$17.9M
P/E ratio
-0.32x
52-week range
1.05-7.25
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Chembio Diagnostics, Inc. (CEMI)
  • COSCIENS Biopharma Inc. (CSCI)
  • Dole plc (DOLE)
  • Elutia Inc. (ELUT)
  • Kineta, Inc. (KA)
  • Lucira Health, Inc. (LHDX)
  • MetaVia Inc. (MTVA)
  • Nymox Pharmaceutical Corporation (NYMXF)

Recent insider activity

  • Desrochers Christine — D-Return (81465 shares) on 2023-09-05
  • Augusti Mark A — A-Award (17778 shares) on 2023-09-05
  • Augusti Mark A — D-Return (190277 shares) on 2023-09-05
  • Fischetti Gary P — D-Return (10470 shares) on 2023-09-05
  • BIENKOWSKI CARRIE — D-Return (19909 shares) on 2023-09-05

Open Conformis, Inc. (CFMS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.